title: [An 80-year-old woman with non-resectable pulmonary adenocarcinoma that responded to concomitant use of gemcitabine and vinorelbine].
abstract: An 80-year-old female with non-resectable pulmonary adenocarcinoma was treated with five courses of chemotherapy consisting of gemcitabine (GEM) 1,000 mg/m2 plus vinorelbine (VNR) 25 mg/m2 (days 1 and 8, every 4 weeks). A partial response (PR) was achieved, and her complaints abated and quality of life (QOL) improved. Although gastro-intestinal symptoms and bone marrow suppression were observed as side effects, they were within a tolerable range and did not interfere with the therapy. Anti-cancer chemotherapy for non-resectable lung cancer might be worth consideration even for elderly patients more than 80 years of age.
authors.affiliation: Division of Internal Medicine, Funabashi Municipal Medical Center.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tabeta
authors.forename: Kazuhisa
authors.initials: K
authors.lastname: Sugito
authors.forename: Atsuko
authors.initials: A
authors.lastname: Tokuda
authors.forename: Masayo
authors.initials: M
authors.lastname: Ohyama
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011788:Quality of Life; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives
chemical_list: D003841:Deoxycytidine; D014747:Vinblastine